E-viri
Recenzirano
Odprti dostop
-
Dreger, Peter; van Biezen, Anja; Brukx, Kees; Boogaerts, Marc; Michallet, Mauricette; Milligan, Donald; Niederwieser, Dietger W.
Blood, 11/2005, Letnik: 106, Številka: 11Journal Article
Treatment-related myelodysplastic syndromes and acute myeloblastic leukemia (t-MDS/AML) have emerged as relevant complications of autologous stem cell transplantation (ASCT) for follicular lymphoma. Given the fact that also fludarabine-cyclophosphamide combination chemotherapy, which is increasingly used for primary treatment in CLL, has been implicated in induction of secondary stem cell disorders, t-MDS/AML might be a substantial problem after ASCT for CLL, too. Therefore the purpose of this study was to analyze the incidence and characteristics of t-MDS/AML among those patients who were autografted for CLL and registered in the EBMT database. For each case submitted between 1992 and 2004, centers received a questionaire asking for follow-up information with particular focus on t-MDS/AML. Results: Of 1139 patients identified from the database, a reply was received for 457. After these 457 autotransplants, 18 cases of t-MDS/AML were observed, giving a crude rate of 3.9%. Median time from ASCT to t-MDS/AML was 28 (10–73) months. Patients with t-MDS/AML had received 2 (1–3) lines of conventional chemotherapy prior to ASCT, containing alkylating agents in 92% and fludarabine in 71% of the patients. Only a single patient had been pretreated with combined fludarabine-cyclophosphamide. High-dose regimens comprised total body irradiation in 71% of the t-MDS/AML cases; and mobilized peripheral blood was used as stem cell source in 92%, containing 2.9 (1.4–7.8) CD34+ cells/kg. Treatment of t-MDS/AML consisted of chemotherapy in 17%, ASCT in 6%, and allo-SCT in 17%, whereas the majority of the patients received supportive care only. Median survival from diagnosis of t-MDS/AML was 8 months with 2 of the 3 allografted patients being alive 10 and 13 months post diagnosis, respectively. Conclusions: The incidence of t-MDS/AML after ASCT for CLL does not seem to exceed the range reported for follicular lymphoma. t-MDS/AML generally occurs within the first 6 years post transplant and has a very poor prognosis. A particular impact of fludarabine-cyclophosphamide pretreatment could not be detected.
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.